GlaxoSmithKline has £1.6bn offer rejected

Drugs giant GlaxoSmithKline said it was disappointed that an offer worth £1.6bn (€1.94bn) for US-based Human Genome Sciences (HGS) has been rejected.
Despite an 81% premium to its Wednesday share price, HGS said the move undervalued its business.